Mammoth Biosciences is harnessing the diversity of nature to power the next generation of CRISPR products. Through its discovery of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. With a distinguished team including co-founder and CRISPR-Cas genome editing co-inventor Jennifer Doudna, Mammoth is addressing challenges across healthcare, agriculture, environmental monitoring, biodefense, and more.
Our leadership team is comprised of cutting edge scientific research and business achievement.
Dr. Trevor Martin founded Mammoth Biosciences with the mission to enable the next generation of CRISPR-based synthetic biology products across therapeutics and diagnostics, including a novel class of affordable, effective, and rapid CRISPR-enabled molecular diagnostics that allow individuals worldwide to better understand their health and a novel family of CRISPR Cas14 proteins that can enable in-vivo editing.
Trevor earned his BA from Princeton University and his PhD in Biology from Stanford. His work has been featured in outlets including FiveThirtyEight and The Atlantic. He is the featured healthcare honoree on the Forbes 30 Under 30 list, is on Fortune’s 40 Under 40 list, and is a Malaria No More “10 to END” innovator.
As co-founder and Chief Technology Officer of Mammoth Biosciences, Janice leads the Applied program by implementing CRISPR-based DETECTR technology towards disease detection and other areas. Janice received her Ph.D. in Molecular and Cell Biology in Jennifer Doudna's lab at UC Berkeley. She has authored multiple publications and patents related to CRISPR mechanism and technologies, and co-invented the programmable CRISPR-based detection technology called DETECTR. Janice was selected as a 2019 Forbes 30 Under 30 in Healthcare, and delivered a TEDx talk in 2018 on the potential for CRISPR to democratize diagnostics.
As co-founder and Chief Science Officer of Mammoth Biosciences, Lucas drives the development of next-generation CRISPR products and leads the scientific research program for new discoveries. He focuses on harnessing microbial diversity to build novel CRISPR applications for DNA detection and genome editing. At UC Berkeley, Lucas worked in Jennifer Doudna’s lab and authored multiple scientific papers, the latest of which features his discovery of the newest Cas system to date, Cas14, in Science. He received a BS in Chemistry from Washington University in St. Louis, where he researched bacterial photosynthesis.
Co-founder, Chair of Scientific Advisory Board
As an internationally renowned professor of Chemistry and Molecular and Cell Biology at U.C. Berkeley, Doudna and her colleagues rocked the research world in 2012 by discovering a simple way of editing the DNA of any organism using an RNA-guided protein found in bacteria, known as CRISPR. Doudna is an Investigator with the Howard Hughes Medical Institute and a member of the National Academy of Sciences, the National Academy of Medicine, the National Academy of Inventors and the American Academy of Arts and Sciences. She is also a Foreign Member of the Royal Society and has received many other honors including, the Breakthrough Prize in Life Sciences, the Heineken Prize, the BBVA Foundation Frontiers of Knowledge Award and the Japan Prize.
Chief Business Officer
Peter joined Mammoth from Casebia Therapeutics as Chief Business Officer and Head of Therapeutics. Peter co-founded Casebia as a Joint Venture between Bayer HealthCare and CRISPR Therapeutics and as part of the leadership team moved several assets from concept to preclinical stage. He brings in more than 19 years of pharma and biotech experience to drive Mammoth’s corporate strategy and enable the translation of technology into applications. Prior to Casebia, Peter has been at Bayer in various positions with increasing responsibility both in the US and in Germany covering strategic marketing, business development, project management, and R&D. Peter received his Ph.D. in Organic Chemistry from the University of Marburg followed by postdoctoral studies at Stanford University. He has co-authored more than 45 patents and various scientific publications.
After over 30 years representing biotechnology companies at a prominent intellectual property law firm and as general counsel at a start-up through a successful IPO and subsequent merger, Bill serves as Mammoth’s in-house legal counsel. Although, primarily focusing on worldwide patent strategy in the rapidly developing CRISPR field, he brings considerable experience in building successful companies to the Mammoth team.
Chief Operations Officer
Ted is an experienced Chief Operations Officer at Mammoth Biosciences, where he oversees Mammoth’s go-to-market strategy and growth. After four years at Synthego Corporation, he grew the company from 18 to 250 employees and established product development, manufacturing operations, and commercial programs. Previously, Ted served as Vice President-General Manager for the Protein Function Division at Bio-Rad Laboratories with responsibilities spanning bioprocessing, multiplex immunoassay, imaging, and life science education programs.